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A B S T R A C T
Magnetically responsive microbubbles (MagMBs), consisting of an oxygen gas core and a phospholipid coating
functionalised with Rose Bengal (RB) and/or 5-ﬂuorouracil (5-FU), were assessed as a delivery vehicle for the
targeted treatment of pancreatic cancer using combined antimetabolite and sonodynamic therapy (SDT).
MagMBs delivering the combined 5-FU/SDT treatment produced a reduction in cell viability of over 50% when
tested against a panel of four pancreatic cancer cell lines in vitro. Intravenous administration of the MagMBs to
mice bearing orthotopic human xenograft BxPC-3 tumours yielded a 48.3% reduction in tumour volume relative
to an untreated control group (p < 0.05) when the tumour was exposed to both external magnetic and ultra-
sound ﬁelds during administration of the MagMBs. In contrast, application of an external ultrasound ﬁeld alone
resulted in a 27% reduction in tumour volume. In addition, activated caspase and BAX protein levels were both
observed to be signiﬁcantly elevated in tumours harvested from animals treated with the MagMBs in the pre-
sence of magnetic and ultrasonic ﬁelds when compared to expression of those proteins in tumours from either
the control or ultrasound ﬁeld only groups (p < 0.05). These results suggest MagMBs have considerable po-
tential as a platform to enable the targeted delivery of combined sonodynamic/antimetabolite therapy in pan-
creatic cancer.
1. Introduction
Pancreatic cancer has the lowest survival rate among the 21 most
common forms of cancer with only 3% of patients surviving ﬁve years
after their initial diagnosis [1]. While many other forms of cancer have
seen survival rates increase signiﬁcantly over the past four decades, the
survival rate for pancreatic cancer has remained unchanged. Late pre-
sentation of patients due to the vague symptoms associated with the
disease means only ~20% are eligible for potentially curative resection
at the time of initial diagnosis [2]. Of the remaining ~80% of patients,
~50% present with metastatic disease and ~30% with locally
advanced or borderline resectable pancreatic cancer (LAPC or BRPC)
[3]. While earlier diagnosis and better awareness are key components
of any future strategy to improve survival rates, there is also an urgent
need for improved therapies. Several studies have investigated the
potential of neo-adjuvant chemo- and/or radio-therapy to downstage
tumours and increase the number of patients eligible for resection
[3–5]. Unfortunately, such treatments are often associated with sig-
niﬁcant oﬀ-target eﬀects due to the non-speciﬁc nature of the che-
motherapy regimen. Therefore, the development of targeted treatments
that reduce side-eﬀects related to systemic chemotherapy have en-
ormous potential as neo-adjuvant and palliative pancreatic cancer
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treatments by reducing tumour burden to either enable surgery or to
provide symptom relief.
In a previous study, we demonstrated the utility of ultrasound re-
sponsive microbubbles (MBs) for delivery of drug payloads and en-
capsulated oxygen gas to pancreatic tumours [6]. MBs are lipid or
polymer stabilised gas ﬁlled particles approved for use as contrast
agents in diagnostic ultrasound [7]. At low ultrasound pressures, MBs
oscillate in a relatively symmetric manner resulting in acoustic back-
scatter that enhances the quality of the diagnostic image [8]. Exposure
of cells to low intensity ultrasound can also facilitate a phenomenon
known as sonoporation which causes a transient ‘poration’ of cellular
plasma membranes and the phenomenon is enhanced in the presence of
exogenously-added MBs. Such an approach has been exploited to en-
hance the eﬃcacy of gemcitabine therapy in pancreatic cancer patients
[9,10]. In contrast, at higher acoustic pressures, collapse of the MB
leads to rupture and release of the shell fragments at the target site
[11]. This feature has been exploited by several groups investigating
the potential of MBs as targeted delivery vehicles [12,13]. In our pre-
vious work, we attached the antimetabolite drug 5-ﬂuouracil (5-FU)
and the sonosensitiser Rose Bengal (RB) to the shell of oxygen-loaded
lipid stabilised MBs for the combined antimetabolite and sonodynamic
therapy (SDT) treatment of pancreatic cancer [6]. Signiﬁcant reduc-
tions in the viability of three pancreatic cancer cell lines (BxPC3,
MiaPaCa-2 and Panc-01) and inhibition of the growth of ectopic pan-
creatic BxPC-3 tumours were observed for the combined treatment
when compared to either treatment alone. Antimetabolite therapy is an
established treatment protocol for pancreatic cancer with 5-FU and
gemcitabine among the most commonly used antimetabolite drugs
[14]. In contrast, SDT is an emerging anti-cancer treatment that in-
volves the activation of an otherwise inactive sensitiser drug using low-
intensity ultrasound [15]. The combination of sensitiser and ultra-
sound, in the presence of molecular oxygen, generates cytotoxic levels
of reactive oxygen species (ROS) causing cell death via oxidative stress
[16]. As oxygen is a key substrate for the generation of ROS in SDT, and
since pancreatic adenocarcinoma is characterised as extremely hypoxic,
providing oxygen during SDT can improve the ROS yield and enhance
the therapeutic outcome [17]. While our oxygen carrying MBs have
shown great promise as a platform for targeted oxygen delivery and
enhanced 5-FU/SDT treatment of pancreatic cancer, there remains a
need to demonstrate the eﬀectiveness of this method in an orthotopic
tumour model following intravenous injection of the MB suspension. To
this end, we have reasoned that an additional layer of targeting may be
required to help retain MBs in the tumour vasculature after injection
and enhance the quantity of MBs destroyed at the target site by ultra-
sound exposure. The incorporation of magnetic nanoparticles within
the MB shell is one approach that has been explored to improve the
targeting capability of MBs [18]. Previous work in our laboratory has
demonstrated that externally applied magnetic ﬁelds may be used to
enhance the retention of magnetically-responsive microbubbles at a
target site in an ex vivo model under physiologically-relevant ﬂow rates
[19]. In this manuscript, we assess the ability of oxygen loaded mag-
netic MBs with 5-FU and Rose Bengal attached to their surface, as a
targeted treatment for orthotopic human pancreatic BxPC-3 tumours in
SCID mice. The beneﬁt aﬀorded by incorporating magnetic targeting
into our delivery platform is demonstrated by studies in a ﬂow-phantom
and by therapeutic eﬃcacy studies in vivo.
2. Materials and methods
2.1. Reagents and equipment
1,2-dibehenoyl-sn-glycero-3-phosphocholine (DBPC) and 1,2-dis-
tearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene
glycol)-2000] (DSPE-PEG(2000)) and DSPE-PEG(2000)-biotin were
purchased from Avanti Polar Lipids (Alabaster, Alabama, USA). Oxygen
gas was purchased from BOC Industrial Gases UK and perﬂuorobutane
(PFB) was purchased from Apollo Scientiﬁc Ltd. Phosphate Buﬀered
Saline (PBS) was purchased from Gibco, Life Technologies, UK. Glycerol
and propylene glycol (1 kg, hydrolysed) were purchased from Sigma
Aldrich (UK). Superparamagnetic iron oxide nanoparticles (SPION):
ﬂuidMAG-Lipid (50 nm hydrodynamic diameter) were purchased from
Chemicell (Berlin, Germany). The use of lipid conjugated SPION in this
study was preferred over the use of previously reported isoparaﬃn
stabilised SPION as the addition of lipids to lipid-shelled microbubbles
is likely to be less disruptive to the acoustic response of the system
compared to the addition of isoparaﬃn [19]. These microbubbles have
been extensively characterised and successfully used in previous in vivo
experiments [20]. The method for magnetic microbubble fabrication
used in this study has then been adapted for the use of lipid conjugated
SPION: ﬂuidMAG-Lipid as presented in the following section. MBs were
formed using a Microson ultrasonic cell disruptor, 100 W, 22.5 kHz,
from Misonix Inc. (NY, USA). Optical microscope images were obtained
using a Leica DM500 optical microscope. MB concentration and size
were determined using purpose- written MATLAB software (2010B,
MathWorks, Natick, MA, USA). Rose Bengal sodium salt, NHS-biotin,
MTT assay kit, avidin, chloroacetic acid, 4-dimethylaminopyridine
(DMAP), hydroxybenzotriazole (HOBt), N,N′-dicyclohexylcarbodiimide
(DCC), anhydrous dimethylformamide (DMF), and ethanol were pur-
chased from Sigma Aldrich (UK) at the highest grade possible. Biotin, 5-
ﬂurouracil, di(N-succinimidyl) carbonate and 2-aminoethanol were
purchased from Tokyo Chemical Industry UK Ltd. Error was expressed
as± SEM (standard error of the mean) and statistical comparisons were
established using ANOVA and un-paired Student's t-test.
2.2. Preparation of avidin functionalised magnetic microbubbles
(MagPFBMBs)
Avidin functionalised magnetic MBs were prepared by dissolving
DBPC (4.0 mg, 4.43 μmol), DSPE-PEG(2000) (1.35 mg, 0.481 μmol)
and DSPE-PEG(2000)-biotin (1.45 mg, 0.481 μmol) at a molar ratio of
82:9:9 in chloroform (274 μL). The chloroform solvent was slowly
evaporated by heating the lipid solution at 40 °C overnight to produce a
dried lipid ﬁlm. The lipid ﬁlm was reconstituted in 2 mL of a PBS
(pH 7.4 ± 0.1):propylene glycol:glycerol (8:1:1 v/v) mixture and the
contents heated at 80 °C under stirring for 30 min in a water bath.
FluidMAG-Lipids NPs (150 μL) were then added to the solution and the
mixture was sonicated with a handheld sonicator probe for 1.5 min
(100 W, 22.5 kHz, power setting 4). The headspace of the glass vial was
then ﬁlled with perﬂuorobutane gas (PFB) and the gas/liquid interface
was sonicated for 20 s (power setting 19), producing PFB-containing
magnetic MBs (MagPFBMBs). The vial was immediately sealed and
placed in an ice bath for 10 min. The MagPFBMB suspension was then
centrifuged (100 RCF, 5 min) to remove the excess NPs and non-in-
corporated MB lipids by discarding the infranatant. The microbubble
concentrate was re-suspended in 2 mL of PBS
(pH 7.4 ± 0.1):propylene glycol:glycerol (8:1:1 v/v), avidin in PBS
(50 μL, 10 mg/mL) was added to the suspension and the contents mixed
for 10 min on a rotary shaker. The suspension was centrifuged (100
RCF, 5 min) to remove the excess avidin and the PFBMBs were again re-
suspended in 2 mL of PBS (pH 7.4 ± 0.1):propylene glycol:glycerol
(8:1:1 v/v). MagPFBMBs were analysed using a Leica DM500 optical
microscope to obtain the size distribution and concentration. For this,
10 μL of suspension was diluted in 190 μL of PBS and examined using a
haemocytometer (Bright-Line, Hausser Scientiﬁc, Horsham, PA, USA).
30 images were obtained with a 40× objective lens and analysed with
customised image analysis package in MATLAB (2010B, MathWorks,
Natick, MA, USA). The iron content in the MagPFBMBs was determined
by atomic absorption spectroscopy using a Varian fast sequential
atomic absorption spectrometer. A calibration curve was constructed
using known concentrations of Fe(III) in 0.5 M HCl. Readings were
taken at 248.3 nm, 0.5 nm slit width, 10.0 mA lamp current, with the
following ﬂame settings; ﬂame type: air/acetylene, air ﬂow: 13.50 L/
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min, acetylene ﬂow: 2.00 L/min, burner height: 13.5 mm. A 300 μL
sample of MagMBs was sonicated to destroy the bubbles and dissolved
in 0.5 M HCl. The amount of Fe(III) present in the sample was calcu-
lated by reference to the calibration curve and the total iron content
determined using a magnetite (Fe3O4) Fe(III):Fe(II) ratio of 2:1.
2.3. Preparation of MagO2MB-Rose Bengal and MagO2MB-5FU conjugates
The synthesis of biotin functionalised Rose Bengal [16] and biotin
functionalised 5-FU [6] have been described by us in previous com-
munications. Saturated solutions of biotin-RB and biotin 5-FU were
prepared in a 0.5% (v/v) DMSO: PBS (pH 7.4 ± 0.1) solvent mixture.
100 μL of biotin-5FU and biotin-RB were added to separate samples
(2 mL each) of MagPFBMBs and allowed to mix for 5 min on a rotary
shaker. Both samples were centrifuged (100 RCF, 5 min) to remove
unbound material and PFBMB conjugates were re-suspended in 1 mL of
PBS solution (pH 7.4 ± 0.1). This conjugation/centrifugation process
was repeated three times. The ﬁnal PFBMB-RB and PFBMB-5FU con-
jugates were transferred to glass vials. MagO2MB-RB and MagO2MB-
5FU conjugates were obtained by sparging the MagPFBMB-RB and
MagPFBMB-5FU with pure O2 gas for 2 min and sealing the vial via
crimping. A small sample (100 μL) of both the MagO2MB-RB and Ma-
gO2MB-5FU conjugates was retained and the MB number again counted
using a haemocytometer. The remaining sample was sonicated in an
ultrasonic bath for 5 min to burst the MBs and the Rose Bengal and 5-
FU concentration determined using UV–Vis (ultra violet – visible)
spectroscopy and HPLC (high performance liquid chromatography)
respectively [21].
2.4. Retention of MagMBs in a ﬂow cell using an external magnetic ﬁeld
MagPFBMBs without payload were used in this study to reduce
wastage of biotin-5FU and biotin-RB. 1 × 107 MagPFBMBs were placed
in a 1 mL syringe, connected to an ibidi μ-Slide VI ﬂow chamber using
silicone tubing (1.6 mm internal diameter) and placed in a peristaltic
syringe pump. A single N52 grade NdFeB permanent magnet cube
(12.7 mm) with an internal magnetization of 1.14 × 106 A/m was po-
sitioned 1 mm from the base of the ﬂow chamber. Values for a ﬁeld of
0.46 T and gradient of 83.1 T/m inside the ﬂow chamber were calcu-
lated using a model described and experimentally veriﬁed previously
[22], whereby the ﬁeld was determined by breaking the magnet into a
3-dimensional lattice of evenly-distributed point moments, and sum-
ming the contributed dipole ﬁeld from each moment. The MagPFBMBs
were pumped through the ﬂow chamber at a rate of 0.6 mL/min. Once
the syringe was empty, the magnetic ﬁeld was removed and 1 mL of
PBS (pH 7.4 ± 0.1) added to the syringe to ﬂush the ﬂow chamber's
content into a clean vial. Collected MBs were counted using the method
described above. As a control, the experiment was repeated in the ab-
sence of a magnetic ﬁeld but under otherwise identical conditions. The
number of MBs collected during the PBS ﬂush was again recorded.
2.5. In vitro cell viability
Human primary pancreatic adenocarcinoma cell lines Mia PaCa-2
and Panc-1, were maintained in DMEM medium. The mouse primary
pancreatic adenocarcinoma T110299 derived from a GEM mouse (KPC
and a gift from Prof. J. Siveke, Technical University of Munich,
Germany), was also maintained in DMEM medium while the human
primary pancreatic adenocarcinoma cell line BxPc-3 was maintained in
RPMI-1640 medium, all of which were supplemented with 10% (v/v)
foetal bovine serum and grown in a humidiﬁed 5% CO2 atmosphere at
37 °C. These cells were plated into the wells of a 96-well tissue culture
plate at a concentration of 5 × 103 cells per well and incubated for 24 h
at 37 °C in a humidiﬁed 5% CO2 atmosphere. The media was then re-
moved from each well and replaced with 100 μL of treatment suspen-
sion and 100 μL of fresh medium. This resulted in a ﬁnal MB count and
RB or 5-FU concentration as follows: MagO2MB-RB: 106 MB, [RB]
= 5 μM; MagO2MB-5FU; 107 MB, [5-FU] = 100 μM and combined
MagO2MB-RB/MagO2MB-5FU: 107 MB, [RB] = 5 μM, [5-FU]
= 100 μM. Where required, individual wells were then placed in direct
contact with the emitting surface a Sonidel SP100 sonoporator with
ultrasound gel used to mediate contact. Each well was treated with
ultrasound for 30 s, using a frequency of 1 MHz, an ultrasound power
density of 3.0 W cm−2 (ISATP; spatial average, temporal peak) corre-
sponding to a peak to peak pressure of 0.8 MPa in water and 0.5 MPa
inside the well as measured with a needle hydrophone (Precision
Acoustics, Dorset, UK); and a duty cycle of 50% (pulse
frequency = 100 Hz). The solution was then removed from the wells
and fresh medium added (200 μL). Plates were incubated in a humi-
diﬁed 5% CO2 atmosphere at 37 °C for 21 h and cell viability de-
termined using an MTT assay [23]. Results were compared with those
obtained using untreated cells and cells exposed to ultrasound treat-
ment alone.
2.6. Treatment of orthotopic BxPC-3 Luc tumours in SCID mice
All animals employed in this study were treated humanely and in
accordance with licenced procedures under the UK Animals (Scientiﬁc
Procedures) Act 1986. BxPc-3 Luc cells were maintained in RPMI-1640
medium supplemented with 10% foetal calf serum as described above.
Cells (1 × 106) were re-suspended in 100 μL of Matrigel® and ortho-
topically implanted into the head of the pancreas of female Balb/c SCID
(C·B-17/IcrHan®Hsd-Prkdcscid) mice. 19 days after implantation, ani-
mals were randomly distributed into 3 groups (n = 4). Following in-
duction of anaesthesia (intraperitoneal injection of Hypnorm/
Hypnovel), a 100 μL mixture of PBS containing MagO2MB-RB/
MagO2MB-5FU (MB = 1.6 × 108, [RB] = 350 μM and [5-FU]
= 700 μM) was administered by tail vein injection to Groups 2 & 3
while Group 1 received vehicle only. For Group 2, ultrasound
(frequency = 1 MHz, ultrasound power density = 3.5 Wcm−2 ISATP;
spatial average temporal peak, corresponding to a free ﬁeld peak to
peak pressure of 0.85 MPa, duty cycle = 30% and pulse repetition
frequency = 100 Hz) was directed to the tumour region (determined
using prior bioluminescent imaging) via the abdomen for 3.5 min
during and after injection (3.5 min total). For Group 3, in addition to
ultrasound using the above parameters, a stack of permanent magnet
discs (arranged to deliver the optimal magnetic force to the tumour
region) [24] was directed to the tumour region (again via the abdomen)
for 3.5 min during and after injection (3.5 min total), resulting in an
approximate magnetic ﬁeld at the tumour of 0.10 T and gradient
14.9 T/m. Treatments using the above conditions were repeated on
Days 20 and 21 with animals sacriﬁced on Day 28. Tumours were then
surgically excised and tumour volumes determined by direct measure-
ment.
2.7. Determination of apoptotic marker expression in tumours post
treatment
Following the determination of tumour volume a single cell sus-
pension was prepared from the excised tumours. This involved homo-
genising the tumour tissue in 4% FCS in RPMI 160 μL (30 mg/mL)
collagenase type II, 50 μL (2 μg/mL) DNAse and stirring for 15 min at
room temperature. A further 160 μL of collagenase II was subsequently
added and the contents stirred for a further 15 min. The mixture was
ﬁltered through a 100 μm ﬁlter, centrifuged at 1700 rpm for 5 min and
re-suspended in 1 mL of Red Cell Lysis Buﬀer (RCLB) for 10 min. RCLB
was neutralised by adding media containing FCS and cells were re-
covered by centrifuging at 1700 rpm. The pellet was washed twice with
PBS, centrifuged and re-suspended in 700 μL PBS buﬀer. For BAX ex-
pression, 300 μL of single cell suspension in staining buﬀer was per-
meabilised using BD permeablisation buﬀer (BD Biosciences UK).
Permeabilised cells were re-suspended in 300 μL of staining buﬀer
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containing BAX antibody (Cell Signalling Technology, D2E11) (10 μg/
mL) and incubated for 30 min at room temperature. The cells were
washed in ice cold PBS and the cell pellet was re-suspended in FITC
secondary antibody (Abcam, ab6717-1) for 1 h. Cells were washed
three times by centrifugation at 400 RCF for 5 min in ice cold PBS, re-
suspended in 650 μL of PBS buﬀer nd analysed by ﬂow cytometry. For
active caspase expression, the Pan Caspase NIR probe kit (Vergent
Bioscience) was used according to the manufacturer's instructions. The
kit utilizes the caspase family inhibitor VAD-FMK conjugated to a near
IR dye (780-VAD-FMK) as a marker that irreversibly binds to activated
caspases in apoptotic cells. Essentially, 300 μL of tumour single cell
suspension diluted in staining buﬀer was centrifuged, the pellet re-
suspended in 300 μL of 1XCAS-MAP NIR probe and incubated at room
temperature in the dark for 1 h. Cells were washed three times by
centrifugation at 400 RCF for 5 min in ice cold PBS and re-suspended in
650 μL of staining buﬀer and analysed by ﬂow cytometry. qRT-PCR was
used to investigate the expression of TMBIM1 in tumours as previously
described [6]. Brieﬂy, RNA was extracted from microdissected slides
using the RecoverAll Kit (Life Technologies, Paisley, UK). cDNA
synthesis was carried out using the Superscript III First Strand cDNA
synthesis kit (Life Technologies, Paisley, UK) using the reverse primer
of each of TMBIM1 (transmembrane BAX inhibitor motif containing 1)
and the two housekeeping genes;18S rRNA and b-actin. qRT-PCR was
carried out using the SYBR Green kit on the CFX96 instrument (BioRad,
UK). The qRT-PCR cycle was as follows: 95C for 3 min, 95C for 10 s,
60C for 45 s for 40 cycles. For analysis, the geometric mean of 18S
rRNA and b-actin was taken as the single housekeeping value. Statis-
tical comparison between the groups was carried out using two-way
ANOVA with Bonferroni post-hoc analysis. The primers used to in-
vestigate the TMBIM1 expression are shown in the table below.
Primer Sequence
TMBIM1 Forward CATCACTGCGGTGGTATCCA
TMBIM1_Reverse GTATTGGAAGTAGAGCACAATGCTAGT
β-Actin Forward CGTGGGCCGCCCTAGGCACCA
β-Actin Reverse TTGGCCTTAGGGTTCAGGGGGG
18SrRNA_Forward TGACTCAACACGGGAAACC
18SrRNA_Reverse TCGCTCCACCAACTAAGAAC
2.8. Toxicity determination of MagO2MB-5FU and MagO2MB-RB
conjugates
Healthy MF1 mice (8 weeks old) were randomly distributed into
four groups (n = 10). Group 1 received no treatment; Groups 2 & 3
received a tail vein injection (100 μL) of 5-FU (115 mM) or RB
(1.03 mM) respectively and Group 4 received a tail vein injection
(100 μL) containing a suspension of MagO2MB-RB/MagO2MB-5FU
([MB] = 2.3 × 108, [RB] = 570 ± 15 μM, and [5FU]
= 503 ± 7 μM]) on Day 1 and Day 8. Pre-treatment tail vein bleeds
(0.10 mL) were collected in lithium heparinised tubes on Day 0 with the
post-treatment bleeds taken in a similar manner on Day 15. Blood
samples were sent to CTDS Ltd. (Leeds, UK) for whole blood and plasma
biochemical analysis. Urea, alanine aminotransferase (ALT), red blood
cell (RBC), haemoglobin (Hb), haematocrit (HCT), mean corpuscular
volume (MCV), mean corpuscular haemoglobin (MCH), mean corpus-
cular haemoglobin concentration (MCHC), platelet, white blood cell,
neutrophil and lymphocyte levels were determined using accredited
protocols. Following the Day 15 bleed, mice were then sacriﬁced and
the liver and kidneys were surgically excised and placed in a formalin
free tissue ﬁxative solution (Sigma-Aldrich) for 24 h. It should be noted
that the liver was chosen in these studies because it has been shown that
MB are removed from circulation by that organ following intravenous
administration. The tissue was then placed in an automated Leica
TP1020 tissue processor and passed between increasing concentrations
of ethanol followed by xylene and paraﬃn wax 24 h later. The wax
embedded tissue samples were placed in moulds containing paraﬃn
wax. Once the wax blocks had solidiﬁed, 5 μm sections were cut, placed
on a glass slide and stained with haematoxylin and eosin (H & E) using
an automated staining protocol. In some cases, additional stains (i.e.
reticulin, Masson's trichrome, Perl's Prussian blue stain) were used if
required. The stained sections were reviewed histologically by pathol-
ogists with expertise in liver and renal pathology. Liver architecture
was initially assessed to establish if there was signiﬁcant remodelling or
ﬁbrosis. The various liver compartments were subsequently examined
for pathological changes. Portal tract and lobular inﬂammation grading
was adapted from the Ishak (modiﬁed HAI) system [25]. Portal tract
inﬂammation was graded numerically from 1 (none) to severe, aﬀecting
all portal tracts (5). Lobular inﬂammation was assessed at 10× mag-
niﬁcation and graded as 1 (none) to 4 (severe, typically averaging> 10
foci per 10× ﬁeld). Fatty liver disease grading, referred to as steatosis/
steatohepatitis, was undertaken based on parameters assessed in the
NAFLD activity score [26]. In short, steatosis was graded based on a
visual estimate of the percentage of liver cells aﬀected as 1 = none
or< 5%; 2 = mild, (5–33%); 3 = moderate (34–66%) and 4 = severe
(> 67%). Kidney analysis was undertaken following a similar approach
assessing the glomerular cellularity, glomerular basement membrane,
tubular vacuolation, interstitial inﬂammation, interstitial ﬁbrosis,
vessel integrity and the collecting system. Statistical analysis was un-
dertaken using a Student's t-test where the MagO2MB-RB/MagO2MB-
5FU group was compared directly with the 5-FU, RB and untreated
groups.
3. Results and discussion
Magnetic microbubbles (MagMBs) were prepared by sonication of
DBPC, DSPE-PEG(2000) and DSPE-PEG(2000)-biotin lipids in the pre-
sence of PFB gas and superparamagnetic iron oxide nanoparticles (NPs).
The magnetic nanoparticle formulation comprised an iron oxide core
with a lipid coating to facilitate incorporation of the magnetic nano-
particles into the MB shell. The PFB containing MagMBs (MagPFBMBs)
produced had an average diameter of 1–2 μm with a concentration of
approximately 1 × 109 MB/mL as determined by analysis of optical
microscopy images (Fig. 1).
The iron content of the MagPFBMBs was also determined using
atomic absorption spectroscopy and revealed the MBs contained
0.286 mg/109 MBs total iron content. Following isolation of the
MagPFBMBs by centrifugation and surface coating with avidin, bioti-
nylated Rose Bengal and biotinylated 5-FU were added to separate
batches of the MagPFBMBs to generate Rose Bengal loaded MagPFBMBs
(MagPFBMB-RB) and 5-FU loaded MagPFBMBs (MagPFBMB-5FU) re-
spectively. The PFB core gas was then exchanged with oxygen by
sparging with pure oxygen gas for 2 min generating the MagO2MB-RB
and MagO2MB-5FU conjugates (Scheme 1).
To determine the magnetic response of the MB platform, suspen-
sions of MagMBs (1 mL) were placed in a syringe and pumped through a
ﬂow chamber (0.6 mL/min) with a ﬁxed magnet (0.46 T) positioned on
the underside of the ﬂow chamber during the course of the experiment.
A control study was also performed in the absence of a ﬁxed magnet but
under otherwise identical conditions. The number of MBs retained in
the ﬂow cell at the end of each experiment were counted and the results
are shown in Fig. 2. A signiﬁcant increase in the number of MBs
(p < 0.01) was observed when the ﬁxed magnet was present in-
dicating the ability of the MagMBs to be retained against ﬂow using an
external magnetic ﬁeld. Blood ﬂow rates within the human body vary
considerably depending on vessel type and size with blood leaving the
aorta (2400 cm min−1) at a ﬂow rate approximately 3 orders of mag-
nitude greater than in capillaries (1.8 cm min−1) [27]. In tumours, the
increased viscous and geometrical resistance presented by the vascu-
lature can compromise its blood ﬂow, meaning the average velocity of
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blood in tumour vessels can be an order of magnitude lower than in
normal vessels [28]. Therefore, the ﬂow rate used in the current study
was towards the upper limit of rates chosen to study tumour perfusing
resistivity which suggests that magnetic targeting may be eﬀective in
helping retain the MBs in the tumour vasculature and allowing a greater
proportion to be destroyed in an applied acoustic ﬁeld.
In order to retain a useful proportion (10%) of injected micro-
bubbles at these blood ﬂow rates, an estimated magnetic ﬁeld gradient
of 0.15 T/m would provide suﬃcient force to capture super-
paramagnetic particles ﬂowing the capillary vessels [29]. When con-
sidering the possible translation of such technology to the clinic, both
transabdominal and endoscopic sources are viable methods for the
delivery of magnetic ﬁelds to the pancreas. In the context of the above
capillary ﬂow rates, optimized permanent magnet designs with a vo-
lume of 1.02 cm3 [20] would be capable of targeting a tumour through
the duodenal wall as part of an endoscopic probe, where the approx-
imate distance to the head of the pancreas is in the region of 10 mm. In
the case of transabdominal delivery, where the distances are more
variable depending on the patient's body to mass index (BMI), the op-
timized permanent magnet volume would be in the region of 1.66 cm3,
based on a distance of 50 mm from the outside of the abdomen to the
pancreas. Even at ﬂow rates 5 times higher than the capillary ﬂow rate
used above, the estimated ﬁeld gradient to retain the same fraction of
MBs would be 2.48 T/m, requiring permanent magnet volumes in the
region of 1.5 cm3 for an endoscopic device, which is readily achievable
[30]. Given endoscopic ultrasound (EUS) analysis is a common
Fig. 1. (a) Photomicrograph taken with a 40× objective
lens of MagMBs after centrifugation (300 RCF, 5 min) and
after dilution (1:20) in PBS. Scale bar is 20 μm. (b) Size
distribution of MagMBs obtained from analysis of 30 optical
microscope images. White boxes on the left represent mi-
crobubbles detected by the image analysis software but
smaller than 450 nm, the optical resolution of the system.
MagO2MB-RB
MagO2MB-5FU
Scheme 1. Schematic representation of the MagO2MB-5FU
and MagO2MB-RB conjugates.
Fig. 2. Plot of MBs retained after injection through a ﬂow-cell in the presence and ab-
sence of a ﬁxed magnet.
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diagnostic tool used in staging pancreatic cancer, a EUS device con-
ﬁgured to deliver both magnetic and ultrasonic ﬁelds is one possibility
for the translation of this technology to clinic.
In a previous study, we demonstrated the beneﬁt of combining Rose
Bengal mediated SDT and 5-FU treatment, delivered using a non-mag-
netic O2MB platform, for the treatment of pancreatic cancer [6]. In the
current study, we were keen to ensure that the presence of redox active
Fe(II) and Fe(III) in the MB shell, would not hamper the eﬀectiveness of
SDT or 5-FU treatment. Therefore, the next step was to determine the
toxicity of the combined treatment in a panel of pancreatic cancer cell
lines. Human pancreatic BxPC-3, MiaPaCa-2 and Panc-01 cells were
chosen as targets in addition to the T110299 cell line [31]. The latter
was isolated from a primary pancreatic tumour in the KPC model
(Ptf1a-Cre; LSL-KrasG12D and Ptf1aCre; LSL-KrasG12D; LSL-Trp53ﬂ/R172H
mice, respectively, that were back-crossed on a C57BL/6 background).
The cells were seeded in 96 well plates and treated with a suspension of
either MagO2MB-5FU, MagO2MB-RB or combined MagO2MB-5FU/Ma-
gO2MB-RB treatment in the presence of ultrasound. Untreated cells and
cells treated with ultrasound only were used as controls.
The results are shown in Fig. 3 and reveal a signiﬁcant reduction
(p < 0.001) in cell viability for all cell lines that received combined
SDT and 5-FU treatment with reductions> 50% relative to the un-
treated cells. In contrast, both the MagO2MB-5FU and MagO2MB-RB
formulations demonstrated only minor reductions (< 10%) in the ab-
sence of ultrasound treatment meaning it was possible to control the
generation of cytotoxicity using the ultrasound stimulus. Therefore,
these results suggest that application of ultrasound not only disrupts the
MBs releasing the encapsulated O2 gas and the attached Rose Bengal/5-
FU into the extracellular medium but also activates Rose Bengal leading
to ROS generation and the observed cytotoxic eﬀect [32]. It is also
possible that application of the ultrasound could be enhancing the ac-
tion of 5-FU by means of sonoporation. Indeed, it has been shown that
this strategy can be employed to enhance the action of cancer che-
motherapeutics by aﬀording transient intracellular access of the drug
via sonoporation [33].
While the in vitro cytotoxicity of the combined 5-FU/SDT treatment
was encouraging, in vivo experiments are essential to identify the
beneﬁt of magnetic targeting. To this end, orthotopic human xenograft
BxPC-3-Luc pancreatic tumours were established in SCID mice.
Nineteen days following implantation the mice were randomly dis-
tributed into three groups (n = 4). Group 1 received no treatment;
Group 2 received a MagO2MB-5FU/MagO2MB-RB suspension adminis-
tered intravenously with the tumour region exposed to low-intensity
ultrasound during and following injection for a total exposure of
3.5 min. Group 3 also received an IV injection of the MagO2MB-5FU/
MagO2MB-RB suspension but in addition to ultrasound treatment, a
Fig. 3. Plot of % cell viability for (a) BxPC-3 (b) T110299
(c) MiaPaCa-2 and (d) Panc-01 after treatment with (i)
untreated, (ii) ultrasound only (iii) MagO2MB-5FU only (iv)
MagO2MB-RB only, (v) combined MagO2MB-RB and
MagO2MB-5FU and (vi) combined MagO2MB-RB and
MagO2MB-5FU plus ultrasound. ***p < 0.001 for (vi)
compared to either (ii), (iii), (iv), or (v).
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permanent magnet was also directed at the tumour during ultrasound
treatment (3.5 min). Treatments were repeated on Days 20 and 21 with
the mice sacriﬁced on Day 28 [34]. This treatment schedule was de-
termined on the basis of a previous pilot study where multiple treat-
ments in close succession were shown to be beneﬁcial over a single
treatment. In addition, as our primary goal is to use this technology as a
neo-adjuvant treatment to downstage tumours in advance of surgery,
aggressive treatment of the tumours with three successive administra-
tions was the preferred choice and as the technology is targeted, sig-
niﬁcantly lower concentrations of RB and 5-FU are used compared to
standard systemic administration. Once the mice were sacriﬁced, the
tumours were surgically excised and volumes determined with the re-
sults for the three groups shown in Fig. 4.
A statistically signiﬁcant reduction in tumour volume of 48.3%
(p < 0.05) was observed for Group 3 relative to control Group 1, while
for Group 2 an obvious downward trend in tumour volume (27.9%) was
detected although this was not found to be statistically signiﬁcant. This
improvement in eﬃcacy in the presence of a magnetic ﬁeld could be
due to more MBs being retained in the tumour microenvironment, so
that ultrasound exposure can enable enhanced deposition of MB pay-
loads and subsequent activation of the sensitiser. Although the latter
would require veriﬁcation by further experimentation, our suggestion is
corroborated by the observation that, activated caspase and BAX pro-
tein levels were both signiﬁcantly elevated in tumours harvested from
Group 3, when compared to expression of those proteins in tumours
from either of the other 2 groups (p < 0.05) (Fig. 5).
Increases in activated caspase and BAX protein levels are indicative
of increased apoptosis and consistent with the increased treatment ef-
ﬁcacy observed for Group 3. Although BAX and caspase were not sig-
niﬁcantly increased in Group 2, a trend in tumour size reduction was
observed for this group (Fig. 4). In addition, previous studies have
shown that ectopic BxPC-3 tumours receiving the combined treatment
in the absence of a magnetic ﬁeld resulted in decreased tumour size and
expressed markers for increased apoptosis [6]. Although signiﬁcant
diﬀerences exist in the manner in which this and the previous study
were performed both from the perspective of the model type (ortho-
topic vs. ectopic) and that of the dosing regimen (multiple vs. single), it
was felt that the reduction ‘trend’ observed in Group 2 in the current
study (Fig. 4) warranted further consideration. To this end, we have
been able to use qRT-PCR analysis to demonstrate that TMBIM1 (en-
coding transmembrane BAX inhibitor motif containing 1) was sig-
niﬁcantly downregulated in tumours receiving the combined treatment
in the absence of a magnetic ﬁeld (Fig. 5). Since TMBIM1 is an inhibitor
of BAX [35], its down regulation in these tumours could lead to en-
hanced BAX-mediated apoptosis without an observable change in BAX
concentration. However, the authors do realise that the data presented
in Figs. 4 and 5 were derived from tumours removed at a speciﬁc time
point (9 days) following treatment and these data may diﬀer if longer or
shorter time-points were chosen. Continuing studies will include a more
in-depth examination of gene expression at various time points in order
to more clearly elucidate the interplay between both of these genes and
their role in treatment-induced apoptosis.
It was also found during the above studies that animals receiving the
magnetically-responsive platform did not suﬀer any overt adverse ef-
fects and no signiﬁcant change in body weight was observed over the
course of the experiment (Fig. 6a). To investigate the aspect of safety
Fig. 4. (a) Photographs of orthotopic BxPC-3 Luc tumours removed from SCID mice
28 days following implantation after (i) no treatment (top), (ii) treatment with combined
MagO2MB-RB and MagO2MB-FU plus ultrasound (middle) or (iii) treatment with
MagO2MB-RB and MagO2MB-FU plus ultrasound and magnet (bottom). Treatments were
administered on Day(s) 19, 20 and 21. (b) Plot of % change in tumour volume relative to
untreated for mice treated with (ii) or (iii) above. *p < 0.05 for (iii) compared to (i). A
one-way ANOVA, post-Hoc test showed the same signiﬁcance as above.
Fig. 5. (a) Plot showing presence of active caspase in single cell suspensions of tumours
removed from SCID mice 38 days following implantation after treatment with (i) no
treatment (left), (ii) treatment with combined MagO2MB-RB and MagO2MB-5FU plus
ultrasound (middle) or (iii) treatment with MagO2MB-RB and MagO2MB-5FU plus ul-
trasound and magnet (right). Fluorescence indicates caspase activity which is reﬂective of
apoptosis and was determined using the Pan Caspase probe (Pan Caspase NIR from
Vergent Bioscience) via ﬂow cytometry. Treatments were administered on Days 19, 20
and 21. (b) BAX protein expression of the same single cell suspensions via ﬂow cytometry.
*p < 0.05 for (iii) compared to (i). (c) Relative expression of TMBIM1 in untreated
control tumours and those receiving combined treatment. ***p < 0.001.
Y. Sheng et al. Journal of Controlled Release 262 (2017) 192–200
198
further, a more detailed toxicology study was undertaken. This involved
administering the MagO2MB-5FU/MagO2MB-RB suspension to 10
healthy non-tumour bearing MF1 mice by tail vein injection on Days 0
and 8. Similar experiments were undertaken involving MF1 mice
treated with 5-FU or Rose Bengal alone at concentrations higher than
those present on the MagMBs to reﬂect clinical doses, while untreated
animals served as a control group. Blood samples were harvested from
each group of animals on Day 15 and analysed for a range of key bio-
chemical markers (Fig. 6b). No major diﬀerences in proﬁle were ob-
served between the MagO2MB-5FU/MagO2MB-RB group and the other
groups that would raise any concern regarding toxicity of the combined
MB-based treatment. Indeed ALT activity, which is a measure of liver
function, was lower in the MagO2MB-5FU/MagO2MB-RB group com-
pared to the other groups. While there was an increase in platelet and
lymphocyte levels for the MagO2MB-5FU/MagO2MB-RB group relative
to the untreated group, levels were also raised in 5-FU and Rose Bengal
treated animals and the diﬀerences between these groups were not
signiﬁcant.
Similarly, there was evidence of mild neutropenia in the three
treatment groups relative to the untreated group, but again the diﬀer-
ence between the MagO2MB-5FU/MagO2MB-RB group and the 5-FU
and RB groups was not signiﬁcant. Furthermore, histological analysis of
liver and kidney sections removed post-mortem on Day 16 also revealed
no signiﬁcant changes between the MagO2MB-5FU/MagO2MB-RB
group and the 5-FU or RB treated groups (Fig. 7).
There was evidence of a slight increase in liver steatosis score for the
MagO2MB-5FU/MagO2MB-RB group but this was not signiﬁcant when
compared to the 5-FU or RB groups. Liver steatosis, also known as fatty
liver disease, is normally a consequence of dietary or lifestyle habits but
can also be inﬂuenced by certain chemotherapeutic drugs including
antimetabolites [36]. The slight increase in score for the MagO2MB-
5FU/MagO2MB-RB group relative to 5-FU or RB may be due to the
uptake and metabolism of the lipid component of the MBs and on that
basis is likely a transient change of limited clinical signiﬁcance. Ana-
lysis of kidney sections showed slightly raised levels of glomerular
cellularity and tubular vacuolation for the MagO2MB-5FU/MagO2MB-
RB group, but again these levels were also raised in the 5-FU and RB
groups and the diﬀerences were non-signiﬁcant. Some of the tubular
vacuolation may have been artefactual, possibly ﬁxation related, as it
was observed in both treated and untreated groups. It must be stressed,
however, that any eﬀect observed in the liver or kidney histology
analysis was deemed to be mild and in no case did the mean score
exceed 2. Collectively, these results indicate the potential of O2MagMBs
as a safe and eﬀective platform for the delivery of combined anti-
metabolite and SDT treatment of pancreatic cancer (Fig. 8).
4. Conclusions
Magnetically responsive MBs were successfully prepared and shown
to be retained at a target site in the presence of an externally applied
magnetic ﬁeld. When decorated with the sensitiser Rose Bengal and the
antimetabolite 5-FU, the MagO2MB conjugates produced reductions
of> 50% in the viability of four pancreatic cancer cell lines upon
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Fig. 6. (a) Average body weight of mice recorded following treatment with vehicle only
(triangles), a suspension of MagO2MB-RB/MagO2MB-5FU + ultrasound (squares), or a
suspension of MagO2MB-RB/MagO2MB-5FU + ultrasound + magnet (circles). (b) Whole
blood and serum biochemistry analysis from healthy MF1 mice (i) untreated control, or
treated with (ii) a suspension of MagO2MB-RB/MagO2MB-5FU, (iii) 5-FU alone, or (iv) RB
alone.
Fig. 7. Scoring for sections of (a) liver and (b) kidney following (i) no treatment, or
treatment with (ii) 5-FU alone, (iii) RB alone, or (iv) a suspension of MagO2MB-RB/
MagO2MB-5FU conjugates. Portal inﬂammation scored 1–5 while all other parameters
were scored from 1 to 4. In each case a score of 1 = normal.
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exposure to relatively low intensity ultrasound. The combined appli-
cation of external magnetic and ultrasound ﬁelds during IV delivery of
the MagO2MB conjugates resulted in a 48.3% reduction in orthotopic
pancreatic tumour volumes 9 days after treatment relative to the con-
trol group, while the application of ultrasound alone resulted in a re-
duction of only 27.9%. In addition, a signiﬁcant increase in apoptosis
was observed in tumours that were treated with the MagMB conjugates
and exposed to both magnetic and ultrasonic ﬁelds when compared to
the ultrasound alone or untreated groups. These results highlight the
potential of using a combination of magnetic and ultrasonic ﬁelds to
retain and disrupt MBs in the tumour vasculature. The results also
conﬁrm the eﬀectiveness of combined sonodynamic/antimetabolite
therapy delivered using the MagO2MB platform as a safe, highly tar-
geted and eﬃcacious treatment for pancreatic cancer.
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Fig. 8. Representative H & E stained microscope images of liver (top) and kidney
(bottom) sections taken from animals sacriﬁced on Day 15 following treatment with a
suspension of MagO2MB-RB/MagO2MB-5FU (right) or untreated (left).
Y. Sheng et al. Journal of Controlled Release 262 (2017) 192–200
200
